



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 8 July 2024

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Securities Market Commission the following

OTHER RELEVANT INFORMATION

ROVI's shareholders are hereby reminded that on 10 July 2024, in execution of the resolution adopted by the Ordinary General Shareholders' Meeting of the Company held on 24 June 2024, and as informed in the said resolution, a dividend will be paid out of the profit for the year ended 31 December 2023 and out of the Company's reserves, in the amount of 1.1037 euros gross per each of the outstanding ordinary shares entitled to receive it.

Payment will be made under the following conditions:

| | <u>Euros per share</u> |
|--|-------------------------------|
| Gross dividend per share: | 1.1037000 |
| Withholding tax per share (if applicable): | 0.2097030 |
| Net dividend per share: | 0.8939970 |

The relevant dates of this dividend distribution are as follows:

- Last trading day for ROVI shares entitled to receive the dividend: 5 July.
- Date from which the shares will be traded with no right to receive the dividend (Ex-Date): 8 July
- Date on which the shareholders of record entitled to receive the dividend are determined (Record Date): 9 July



- Payment date: 10 July

The aforementioned amount will be paid through the means that the Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (IBERCLEAR) makes available to its participating entities, being the paying entity Banco Santander, S.A.

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)
Laboratorios Farmacéuticos ROVI, S.A.